[Clinical course of hormone refractory cancer of the prostate].
Analysis of the clinical progression of 61 patients with prostate cancer undergoing hormone therapy. PSA allowed early detection in 86.9% cases. In 25 patients no rescue treatment was instituted, and 36 patients were treated with estramustine phosphate resulting in decreased PSA levels in 58% and objective response in 36%. Of these, 82% showed decreased PSA levels for over six months. Survival rate was higher in respondent, treated patients and comparable in non-respondents, treated versus non treated patients.
D000135:Acid Phosphatase / Q000097:blood; D000206:Actuarial Analysis; D000726:Androgen Antagonists / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004961:Estramustine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011467:Prostate; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D000726:Androgen Antagonists; D014408:Biomarkers, Tumor; D004961:Estramustine; D004054:Diethylstilbestrol; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen
Evolución del cáncer de próstata hormonorrefractario.